You are here: Industry Insights > Novavax

News List

Canadian government strikes deals with Janssen and Novavax for COVID-19 vaccines europeanpharmaceuticalreview
September 03, 2020
The Canadian government has agreed that Janssen will supply the country with 38 million doses of its COVID-19 vaccine, while Novavax has agreed to supply 76 million doses if its vaccine.
Novavax and Canada reach agreement in principle for 76 mn doses of COVID-19 vaccine expresspharma
September 02, 2020
Novavax has announced that it has reached an agreement in principle with the Government of Canada to supply up to 76 million doses of NVX-CoV2373, Novavax’ COVID-19 vaccine.
Novavax to Supply 76M Doses of COVID-19 Vax to Canada contractpharma
September 01, 2020
Pending finalized advance purchase agreement, Novavax will supply doses of NVX-CoV2373 beginning as early as 2Q21.
First patients enrolled in Phase II trial of Novavax COVID-19 vaccine europeanpharmaceuticalreview
August 26, 2020
The Phase II clinical trial to study NVX-CoV2373, the Novavax COVID-19 vaccine candidate, has enrolled its first patient.
Novavax commences Phase 2 clinical trial of COVID-19 vaccine candidate expresspharma
August 25, 2020
Trial to enroll up to 1,500 volunteers in the US and Australia, with approximately 50 per cent between 60 and 84 years of age.
UK Govt. Buys 60 Million Doses of Novavax’ COVID-19 Vax Candidate contractpharma
August 18, 2020
Fujifilm Diosynth Biotechnologies to manufacture antigen component of NVX-CoV2373 in the UK.
UK signs deals with J&J, Novavax for COVID-19 vaccine supplies expresspharma
August 17, 2020
The latest agreements bring Britain’s total number of doses secured to 362 million for a population of 66 million.
Novavax announces collaboration with SK bioscience for COVID-19 vaccine expresspharma
August 14, 2020
SK bioscience will manufacture the vaccine antigen component for use in the final drug product globally during the pandemic period.
Takeda to license Novavax’ Covid-19 vaccine candidate NVX‑CoV2373 pharmaceutical-business-review
August 12, 2020
Novavax has agreed to grant the Japanese licensing rights to NVX‑CoV2373, a vaccine candidate modified from the genetic sequence of the Covid-19 causing SARS‑CoV‑2 virus, to Takeda Pharmaceutical.
AGC Biologics, Novavax Expand Coronavirus Vax Pact contractpharma
August 12, 2020
Expands supply of Matrix-M adjuvant for Novavax’ coronavirus vaccine, NVX-CoV2373, from its facility in Seattle for U.S. supply.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page